Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsJanssen pharma

    Janssen Pharma

    Jump to

    • Dr Reddy's gains on anti-cancer generic Doxil approval, Sun Pharma dips

      The Doxil brand and generic had US sales of USD 196 million for the 12 months ending in March 2017, according to IMS Health. Analyst estimate Dr.Reddy's-Natco to clock anywhere between USD 40 million and 80 million, if there is no incremental competition.

    • Janssen to launch new TB drug through govt's TB programme

      It is the first new TB drug to be launched in more than 40 years and one that offers a cure for drug-resistant strains of tuberculosis. The drug's innovator Janssen Pharma, will be launching the medicine only through the government's TB program, prompting medical practitioners to raise concern about its wider availability.

    • Sun Pharma to enter lucrative oral contraceptive mkt in US

      Sun Pharma is all set to enter the lucrative oral contraceptive market in the US, but the going won’t be easy with the entrenched players like Teva and Watson dominating the market. CNBC-TV18’s Archana Shukla reports Sun will even have to take on its Indian peers like Glenmark and Lupin, who have an early mover advantage.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347